1
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Condition(s):ISS Stage III Plasma Cell Myeloma; Plasma Cell MyelomaLast Updated:July 3, 2023Recruiting
Stage III Multiple Myeloma, AREA[OverallStatus], Open or Pending: 13 Clinical Trials, Page 1 of 2
Include Studies Not Open or Pending
2
Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma
Condition(s):Multiple Myeloma in Relapse; Multiple Myeloma Progression; Multiple Myeloma Stage II; Multiple Myeloma Stage I; Multiple Myeloma With Failed Remission; Multiple Myeloma Stage IIILast Updated:October 5, 2022Recruiting
3
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Condition(s):Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Nonmalignant NeoplasmLast Updated:October 18, 2022Recruiting
4
Registry of Older Patients With Cancer
Condition(s):Chronic Myeloproliferative Disorders; Cognitive/Functional Effects; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol SpecificLast Updated:June 22, 2023Recruiting
5
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis
Condition(s):AL AmyloidosisLast Updated:August 7, 2023Recruiting
6
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
Condition(s):AL AmyloidosisLast Updated:August 14, 2023Recruiting
7
Personalized NK Cell Therapy in CBT
Condition(s):Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Biphenotypic Leukemia; Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia in Remission; Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Acute Myeloid Leukemia With Variant MLL Translocations; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; Chemotherapy-Related Leukemia; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; ISS Stage II Plasma Cell Myeloma; ISS Stage III Plasma Cell Myeloma; Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts; Myelodysplastic Syndrome With Gene Mutation; Myelodysplastic/Myeloproliferative Neoplasm; Previously Treated Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Hodgkin Lymphoma; Recurrent Non-Hodgkin Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Adult Acute Lymphoblastic Leukemia; Secondary Acute Myeloid Leukemia; Therapy-Related Myelodysplastic SyndromeLast Updated:September 8, 2023Recruiting
8
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Condition(s):Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Ann Arbor Stage I Lymphoma; Ann Arbor Stage II Lymphoma; Ann Arbor Stage III Lymphoma; Ann Arbor Stage IV Lymphoma; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Gastroesophageal Junction Adenocarcinoma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Invasive Breast Carcinoma; Kidney Carcinoma; Malignant Hepatobiliary Neoplasm; Malignant Solid Neoplasm; Melanoma; Muscle-Invasive Bladder Carcinoma; RISS Stage I Plasma Cell Myeloma; RISS Stage II Plasma Cell Myeloma; RISS Stage III Plasma Cell Myeloma; Sarcoma; Stage I Bladder Cancer AJCC v6 and v7; Stage I Breast Cancer AJCC v7; Stage I Colorectal Cancer AJCC v6 and v7; Stage I Esophageal Cancer AJCC V7; Stage I Gastric Cancer AJCC V7; Stage I Lung Cancer AJCC v7; Stage I Ovarian Cancer AJCC v6 and v7; Stage I Pancreatic Cancer AJCC v6 and v7; Stage I Prostate Cancer AJCC v7; Stage I Uterine Corpus Cancer AJCC v7; Stage II Bladder Cancer AJCC v6 and v7; Stage II Breast Cancer AJCC v6 and v7; Stage II Colorectal Cancer AJCC v7; Stage II Esophageal Cancer AJCC v7; Stage II Gastric Cancer AJCC v7; Stage II Lung Cancer AJCC v7; Stage II Ovarian Cancer AJCC v6 and v7; Stage II Pancreatic Cancer AJCC v6 and v7; Stage II Prostate Cancer AJCC v7; Stage II Uterine Corpus Cancer AJCC v7; Stage III Bladder Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage III Colorectal Cancer AJCC v7; Stage III Esophageal Cancer AJCC v7; Stage III Gastric Cancer AJCC v7; Stage III Lung Cancer AJCC v7; Stage III Ovarian Cancer AJCC v6 and v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage III Prostate Cancer AJCC v7; Stage III Uterine Corpus Cancer AJCC v7; Stage IV Bladder Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Colorectal Cancer AJCC v7; Stage IV Esophageal Cancer AJCC v7; Stage IV Gastric Cancer AJCC v7; Stage IV Lung Cancer AJCC v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IV Prostate Cancer AJCC v7; Stage IV Uterine Corpus Cancer AJCC v7; Thyroid Gland CarcinomaLast Updated:August 31, 2023Recruiting
9
Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.
Condition(s):Multiple MyelomaLast Updated:June 14, 2022Recruiting
10
A Study of Real Life Treatment for Multiple Myeloma (MM)
Condition(s):Multiple MyelomaLast Updated:February 8, 2023Recruiting